EHA 2023 | The evolution of therapy for Ph+ ALL and Ph- ALL & the role of MRD in this space
Robin Foà
• 11 Jun 2023
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses how therapy is evolving for Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL), highlighting the growing role of immunotherapy in this space, and commenting on the importance of measurable residual disease (MRD)-guided therapy in ALL. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
